CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
Ryan Allway November 8th, 2022 News, Top News REHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ — CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company,... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )